profit from every $100 of sales.
$0$100
QuidelOrtho
$10.74+1.13% today
-51.6% in 1 year
1-year low $9.961-year high $35.38
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What QuidelOrtho sold, what it kept, and what it did with the cash.
Sales went from $3.27 billion in 2022 to $2.73 billion in 2025, with -$1.13 billion of profit last year.
SalesProfit
QuidelOrtho vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| QuidelOrtho | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads QuidelOrtho's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,266 | 2,998 | 2,783 | 2,730 | |
| 1,936 | 1,497 | 1,287 | 1,274 | |
| 983 | 257 | 46 | 55 | |
| 1,094 | 607 | -1,490 | -483 | |
| 549 | -10 | -2,052 | -1,132 | |
| 9.56 | -0.15 | -30.16 | -16.69 | |
| 59.3% | 49.9% | 46.2% | 46.7% | |
| 30.1% | 8.6% | 1.6% | 2.0% | |
| 16.8% | -0.3% | -73.7% | -41.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 8,856 | 8,563 | 6,424 | 5,769 |
| Cash | 293 | 119 | 98 | 170 |
| Total debt | 2,849 | 2,614 | 2,681 | 2,834 |
| Total liabilities | 3,921 | 3,557 | 3,439 | 3,849 |
| 4,935 | 5,006 | 2,985 | 1,921 | |
| 57 | 67 | 67 | 68 | |
| 8.2% | 1.6% | -27.1% | -15.4% | |
| 11.1% | -0.2% | -68.8% | -58.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 885 | 280 | 83 | 105 | |
| 141 | 209 | 195 | 188 | |
| 744 | 71 | -112 | -83 | |
| Dividends paid | – | – | – | – |
| 74 | 7 | 0 | 0 | |
| 48 | 52 | 42 | 46 |
Valuation
- –
- 6.4×
- –
- 0.4×
- 0.3×
- –
- –
- -11.3%
- -153.6%
- 0.0%
Profitability
- 46.7%
- 2.0%
- -41.5%
- -20.7%
- -19.9%
- -3.8%
- -56.3%
- -21.5%
- -21.0%
- 6.7%
Growth
- −5.8%
- –
- +26.0%
- –
- +12.7%
Financial health
- –
- 1.55
- 51.1%
- -5.3×
- 1.43
- 0.80
- 0.47
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 964
Bottom 26%of 898
Bottom 9%of 911
Bottom 8%of 991
What analysts expect
- Average price target
- $17.00
- Range
- $17.00 – $17.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.04 | 0.37 | −110.8% |
| Feb 11, 2026 | 0.46 | 0.43 | +7.0% |
| Nov 5, 2025 | 0.80 | 0.51 | +56.9% |
| Aug 5, 2025 | 0.12 | 0.56 | −78.6% |
| May 7, 2025 | 0.74 | 0.58 | +27.6% |
| Feb 12, 2025 | 0.63 | 0.55 | +14.5% |
| Nov 7, 2024 | 0.85 | 0.31 | +174.2% |
| Jul 31, 2024 | -0.07 | -0.21 | +66.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
13No pass
Benjamin Graham
54No pass
Philip Fisher
26No pass
Peter Lynch
14No pass
Joel Greenblatt
0No pass
Charlie Munger
13No pass
Terry Smith
14No pass
Questions about QuidelOrtho
Is QuidelOrtho a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the QuidelOrtho AI analysis
What does QuidelOrtho do?
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. It is in Medical - Instruments & Supplies.
Does QuidelOrtho pay a dividend?
No. QuidelOrtho does not pay a dividend at the moment.
Is QuidelOrtho stock halal?
No. QuidelOrtho does not pass our halal screen: its debt is 385% of its market value, at or above the 33% limit. How we check
How has QuidelOrtho stock done over the past year?
Down 51.6% over the past twelve months, to $10.74. It traded between $9.96 and $35.38 and is 69.6% below its high.
Who are QuidelOrtho's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with QuidelOrtho's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.